Cellix Bio Publishes CLX-103 Research in International Immunopharmacology: Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of Inflammatory Bowel Diseases
Cellix Bio and Logic Biosciences, Inc., Joint Venture is focussed to develop and commercialize novel therapies and targeted delivery formulations for the management of Pain in various therapeutic indications such as Oral Mucositis and Post-Operative Pain.
Cellix Bio’s CLX-117 pipeline lead candidate qualifies for UConn SPARK Technology Commercialization Fund Program 2016 with the investigative supervision of Dr. Rajesh V Lalla. The award aims to help investigators from UConn-Storrs and UConn Health (UCH) move ideas into the earliest stages of commercialization and development.
Cellix Bio and VClinBio, Inc., Collaboration is focussed to develop and commercialize novel therapies for the treatment of Multiple Sclerosis and Psoriasis. CLX-106 pipeline lead candidates comprises of Novel MonoMethylFumarate Glyceryl Ester molecular entities.
Cellix Bio and New Jersey Medical School, Rutgers; collaboration is focussed to screen novel anti-fungal compounds developed and patented by Cellix Bio. These novel therapies are focussed to address the drug resistance in pathogenic fungal infections.
Cellix Bio bags 2017 Fastest Growing Indian Company Excellence Award. The award will be presented during the National Seminar & Awards Ceremony on “Individual Achievements & National Development” at New Delhi.
Cellix Bio and Texas A&M University collaboration is focussed to screen Gastro-Intestinal Tolerable NSAIDs with improved efficacy and safety profile. Cellix Bio’s Patented Platform Technology driven Diclofenac Novel Long Chain Fatty acid conjugate had low GI ulceration with improved safety and tolerability profile. The collaboration is also extended to investigate the Novel Sulindac and Eflornithine novel molecular conjugates for the effective treatment of GI Polyps.